ABSTRACT

Early detection of progressive multifocal leucoencephalopathy (PML) in the setting of natalizumab therapy currently is performed by rapid evaluation of new symptoms occurring in treated patients. The role of MR scanning has not been investigated but holds promise since MR detection is highly sensitive for PML lesions. The authors report a case of presymptomatic PML of the posterior fossa detected by MR scans. Immediate suspension of natalizumab and plasma exchanges resulted in a rapid decline of natalizumab serum concentration. Intravenous steroids started together with plasma exchanges followed by an oral tapering course were used to minimise the immune reconstitution inflammatory syndrome. No symptoms (beyond mild headache) developed, and the repeat PCR for JC Virus (JCV) DNA detection performed 10 weeks later was negative. This case suggests that: (1) periodic brain MR scans may detect signs of presymptomatic PML in MS patients treated with natalizumab, (2) corticosteroid management of inflammatory reaction may contribute to optimal control of the immune reconstitution inflammatory syndrome routinely seen with natalizumab-associated PML and (3) early radiological detection of PML can have an excellent outcome even in a clinically critical region and despite prior immunosuppressant exposure. The potential benefit of regular MR scanning just using the T2/FLAIR modalities could be further investigated in order to detect early natalizumab-associated PML, leading to benign outcomes.

CASE REPORT

A 29-year-old man diagnosed 17 years earlier with relapsing multiple sclerosis (RMS) remained free of disease activity during 3 years of natalizumab therapy in that he experienced no clinical relapses, disability progression and no new T2 or gadolinium-enhancing T1 lesions on MRI. He had no other significant comorbidities.

The patient’s previous RMS therapy included 4 years of interferon β-1b and six courses of mitoxantrone (12 mg/m² dosed every 2 months, 3 years before initiating natalizumab), which failed to control disease activity. After 153 weeks of natalizumab therapy (38 doses of 300 mg intravenous every 4 weeks) our patient’s sixth routine 6-month follow-up MRI scan depicted six small (1.0 to 3.0 mm) new lesions in the left middle cerebellar peduncle with faint T1 Gd enhancement (figure 1). Consequently, at the 39th scheduled natalizumab infusion (week 153), dosing was suspended, and a cranial MRI 3 weeks later demonstrated a major worsening of the punctuate-shape lesion pattern with 49 small (1.0–5.2 mm) Gd-enhancing lesions in the left middle cerebellar peduncle and left cerebellar hemisphere (week 156, figure 1). Most lesions were also hyperintense in diffusion-weighted imaging, and no oedema or meningeal enhancement was observed. The supratentorial MS lesions were strictly stable in number and volume with no Gd enhancement (figure 2, supplementary material). The only new complaint expressed by the patient was a mild occipital headache lasting 3–4 days, but his neurological examination remained unchanged and the Expanded Disability Status Scale score was stable at 4.0, as were several functional assessments such as the Timed 25-Foot Walk test, the Six-Spot-Step Test, the Timed 100 m Walk test, the Nine-Hole Peg Test, and the 5 s Paced Auditory Serial Addition Test (figure 3, supplementary material). The cerebrospinal fluid analysis (CSF) showed a pleocytosis with 81 white blood cells (91% lymphocytes, 9% monocytes) and eight red blood cells/mm³. The glucose concentration was within the normal range (0.64 g/l), and the protein concentration was mildly elevated (507 mg/l). The IgG concentration was mildly elevated (50 mg/l), and numerous CSF-specific oligoclonal bands were observed. JC polyoma virus (JCV) DNA was detected in CSF using ultrasensitive quantitative real-time PCR (Focus Diagnostics, Cypress, California) (712 copies/ml), and serum anti-JCV antibodies were detected using a two-step ELISA as previously described.

Other CSF and blood analysis were unremarkable (table 1, supplementary material). Based on these observations, we confirmed a diagnosis of asymptomatic progressive multifocal leucoencephalopathy (PML) in the posterior fossa, with an atypical punctuate-shape pattern (week 156). In order to hasten the clearance of natalizumab, we carried out only three plasma exchanges (PLEX, 1.5 volumes) since the last natalizumab infusion had been dosed, 7 weeks before PML diagnosis, with the possible presence of early MRI signs of immune reconstitution inflammatory syndrome (IRIS). Intravenous methylprednisolone (IVMP, 1 g) was initiated together with the PLEX for 5 days, followed by an oral tapering course of 12 weeks, in order to silence the radiological IRIS. After PLEX had been performed, we were informed...
that natalizumab serum concentration was already below the 
limits of quantitation of the assay (ie, <0.5 μg/ml) before PLEX. 
The patient remained strictly symptom-free throughout 
a follow-up of 19 weeks after the last natalizumab infusion, 
15 weeks after the first MRI signs of PML and 12 weeks after 
PLEX (figure 2, supplementary material). Ten weeks after PML 
diagnosis and onset of PLEX-JVMP treatment, a follow-up assay 
using ultrasensitive PCR indicated that CSF was negative for JC 
virus DNA. The CSF pleocytosis had vanished with four white 
blood cells/mm³, and protein concentration decreased at 
426 mg/l. At the time the CSF was normalised (week 166), the 
follow-up brain MRI scans showed a regression of the PML 
lesion volume on T2/FLAIR sequences with a partial resolution 
of T1-Gd enhancement, particularly at the periphery of the 
lesion (figure 1). Brain MRI scans performed at weeks 157, 159 
and 162 displayed intermediate lesion patterns consistent with 
the demonstration of a gradual radiological improvement 
between week 156 and 166 (data not shown).

DISCUSSION
Natalizumab is a highly effective therapy for RMS but 
increased exposure has been associated with an increased risk of 
PML, which is a potentially life-threatening central-nervous-
system infection of oligodendrocytes by the JC polyoma virus.7 
Despite an increased risk of PML in patients with known risk 
factors such as prior use of immunosuppressive agents and 
natalizumab treatment duration of more than 2 years, no clear 
guidelines have yet been drawn, and clinical vigilance remains 
the primary tool for early PML diagnosis. There is an ongoing 
debate about how to appropriately stratify PML risk in natali-
zumab-treated patients.5 8 It was recently reported that anti-
JCV antibodies were detected in 100% of PML patients from 
whom pre-PML serum samples were available up to 187 months 
before clinical diagnosis,5 and as such, anti-JCV antibody 
serostatus is being investigated as potential additional factor to 
stratify PML risk.

Since the initial clinical manifestations of PML can be subtle 
(including isolated mild cognitive changes), it is not surprising 
that the time between the onset of symptoms and PML diag-
nosis can vary considerably, from a few days to several months.7 
The management of natalizumab-associated PML is also 
a matter of debate. A prompt wash-out of serum natalizumab, 
either by PLEX or by immunoadsorption, in order to hasten the 
restoration of CNS immune surveillance, combined with steroid 
therapy to prevent IRIS development, is common practice for 
PML treatment. Recently, it has been reported in a group of 35

![Figure 1](https://journals.bmj.com/content/jnnp/先行/300511.full)

**Figure 1** T2-weighting with fluid attenuation inversion recovery (FLAIR) and T1+Gd MR images of two 
scanning plans separated by 8 mm in the posterior fossa at different stages of a patient’s history with reference to the 
onset of natalizumab therapy. Week 129 examination was the fifth routine 6-monthly brain MR scan. Week 153 
shows the first MR signs of the punctate-shape PML lesion in the left cerebellar peduncle. FLAIR-
hyperintense dots (arrow) were all Gd-enhanced on T1-weighted images. At the time PML diagnosis was 
ascertained at week 156, the lesion massively extended to the left cerebellar hemisphere. When no more 
JC virus DNA was detectable on the CSF at week 166, we observed a significant regression of the multifocal 
lesion volume on FLAIR images together with an increased coalescence. The aspect of Gd enhancement was also modified and then restricted to the central core of the lesion with a decrease in dotted peripheral enhancement in the cerebellar hemisphere.
natalizumab-treated PML cases that enhanced clinical vigilance, including early recognition of symptoms, diagnosis and aggressive management of PML and IRIS are associated with an improved survival rate and clinical outcomes. However, the precise approach should be optimised for each patient with attention to MRI characteristics of PML (including early signs of IRIS) and of the natalizumab serum concentration at the time of PML diagnosis.

In our department, we perform 6-monthly brain MRI scans for all RMS patients treated with natalizumab. In the case of the patient reported here, the MRI features were somewhat unusual. In particular, the punctuate pattern is atypical and might be due to tiny multifocal foci of JC virus proliferation that later coalesce to give rise to the classical appearance of a widespread white-matter disorder and symptoms. Whereas the Gd enhancement is rare in HIV-related PML, it is commonly observed in the context of natalizumab therapy. Gd enhancement of the PML lesions may reflect a breakdown of the blood–brain barrier due to early IRIS associated with the rapid decline of natalizumab serum concentration, which was already undetectable here when the first lesions were observed. Finally, the rapid deterioration of the PML lesion load observed within 3 weeks after the first MRI signs is a strong argument to plead for a rapid CSF screening for JC virus DNA in the context of any new unusual brain lesion in MS patients treated with natalizumab.

This case emphasises that JC virus CNS infection can be detected at a preclinical stage, even in the posterior fossa where small lesions often cause serious disability. The uncoupling between a large PML lesion in a highly functional location, and the absence of clinical expression, is of great interest. In this case, an aggressive corticosteroid regimen initiated during PLEX was associated with a stable clinical course of PML, a favourable evolution of MRI manifestations and clearance of JC virus from CSF. Although the benefits of steroids in natalizumab-associated PML-IRIS have never been and will never be addressed in a randomised clinical trial, at least one study has suggested a clinical benefit in PML-IRIS with HIV infection. Since the theoretical risk of increasing the JC virus load during steroid therapy is considered low with regard to the likelihood of developing detrimental IRIS, many experts have advocated high-dose steroid treatment use in the context of natalizumab-associated PML.

One prior reported case suggests that asymptomatic MRI changes can be captured several months prior to initial manifestation of PML symptoms. The story of the present case suggests that the screening for preclinical signs of PML might be achieved through periodic T2/FLAIR brain MRI scans in patients with known PML risk factors such as prior immunosuppressant exposure, natalizumab treatment duration over 2 years and JC virus seropositivity. However, the required frequency, cost–benefit trade-off and efficacy of such a monitoring remain to be investigated before we firmly consider that it may increase the proportion of early detection of PML in such patients, and improve their chance of avoiding or minimising permanent neurological injury.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics approval was provided by the ethical committee of the CHU of Liège, Belgium.

Contributors RPB and SB contributed substantially to the conception and design, analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published. GM and DC contributed substantially to the conception and design, analysis and interpretation of data, and final approval of the version to be published.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy

Rémy Phan-Ba, Emilie Lommers, Luaba Tshibanda, et al.

*J Neurol Neurosurg Psychiatry* published online October 19, 2011
doi: 10.1136/jnnp-2011-300511

Updated information and services can be found at:
http://jnnp.bmj.com/content/early/2011/10/18/jnnp-2011-300511.full.html

These include:

**Data Supplement**

“Supplementary Data”
http://jnnp.bmj.com/content/suppl/2011/10/18/jnnp-2011-300511.DC1.html

“Supplementary Data”
http://jnnp.bmj.com/content/suppl/2011/10/19/jnnp-2011-300511.DC2.html

**References**

This article cites 14 articles, 7 of which can be accessed free at:
http://jnnp.bmj.com/content/early/2011/10/18/jnnp-2011-300511.full.html#ref-list-1

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/